CONTACT

+91 80 2808 2808

info@biocon.com

Press Releases 2021

Biocon / News – Posts / Press Releases / Press Releases 2021

Biocon Biologics* Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus® Device Patents

Thu, 30-Dec-2021
Posted by: BIOCON

Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval

Thu, 23-Dec-2021
Posted by: BIOCON

Biocon Ltd partners with Tabuk Pharmaceuticals to commercialise its speciality generic medicines in the Middle East

Tue, 07-Dec-2021
Posted by: BIOCON

Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index

Wed, 01-Dec-2021
Posted by: BIOCON

Biocon Biologics and Viatris Announce Insulin Glargine (insulin glargine-yfgn) Injection Will Be Offered Through the Walgreens Prescription Savings Club

Fri, 19-Nov-2021
Posted by: BIOCON

Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection

Tue, 16-Nov-2021
Posted by: BIOCON

Biocon Biologics Collaborates with RSSDI to Expand Access to its Insulins for Children with Type 1 Diabetes on World Diabetes Day

Mon, 15-Nov-2021
Posted by: BIOCON

Biocon Biologics and Viatris Announce Prime Therapeutics Prefers First-Ever Interchangeable Insulin Biosimilar Semglee® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection on its National Formularies

Thu, 04-Nov-2021
Posted by: BIOCON

Biocon Q2FY22 Revenue up 10% at Rs 1,945 Cr; EBITDA up 35% at Rs 551 Cr; Net Profit (before exceptional items) up 11% at Rs 188 Cr;

Fri, 22-Oct-2021
Posted by: BIOCON

Biocon Biologics’ First-Ever Interchangeable Biosimilar Insulin Glargine, Co-Developed with Commercial Partner Viatris, Preferred on Express Scripts’ Largest Formulary in US

Thu, 21-Oct-2021
Posted by: BIOCON

1
2
3